Morgan Stanley analyst Patrick Wood lowered the firm’s price target on Steris to $215 from $225 and keeps an Equal Weight rating on the shares. A combination of rising 10 year rates and GLP-1 pressures have pushed the valuation of the U.S. MedTech sector down and given the material de-rating the firm is upgrading its Industry View on MedTech to Attractive, the analyst tells investors. Volumes remain in strong shape, capital equipment is looking healthy and the firm sees limited expected impact from GLP-1s, the analyst added in a note on the group in which the firm adjusted a number of price targets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on STE:
- Steris (NYSE:STE): JMP Securities Analyst Bullish Following Mixed Q2 Results
- Steris sees FY24 adjusted EPS $8.60-$8.80, consensus $8.75
- Steris reports Q2 adjusted EPS $2.03, consensus $2.01
- STERIS Announces Financial Results for Fiscal 2024 Second Quarter
- STE Upcoming Earnings Report: What to Expect?